The Business Times
The Business Times
Subscribe
Share on FacebookShare on TwitterView more
The Business Times
Create a free account with Business Times for seamless access across SPH Media products.
REGISTER
LOGIN

Companies & Markets

SUBSCRIBERS

Johnson & Johnson forecasts profit decline this year on competition

Its hepatitis C drug Olysio faces competition from Gilead Sciences' Harvoni that combines two drugs in one pill

Published Wed, Jan 21, 2015 · 09:50 PM
Share this article.

New York

JOHNSON & JOHNSON (J&J), the world's biggest maker of healthcare products, forecast lower earnings in 2015 as competition cuts into revenue for some of its best-selling drugs. The shares slumped the most in three months.

Adjusted profit this year will reach US$6.12 to US$6.27 a share, the company said on Tuesday. That figure exclud…

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to  t.me/BizTimes

Consumer & Healthcare

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

Get the latest coverage and full access to all BT premium content.

SUBSCRIBE NOW

Browse corporate subscription here